Observational studyCurrent Alzheimer research2025
Spectral Biomarkers of Functional Brain Network Alteration in Alzheimer's Disease.
Observational study in Current Alzheimer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe primary objective of this study was to examine changes in brain network architecture across multiple frequency bands using spectral analysis of both weighted and binarized functional connectivity networks. This cross-sectional observational study, conducted as a secondary analysis of a publicly available EEG dataset, analyzed spectral coherence measurements from 25 patients with Alzheimer's disease (AD) and 25 age- and sex-matched healthy controls (HC). Nevertheless, the modest sample size and cultural homogeneity of the dataset may limit the statistical power and generalizability of the results. A data-driven thresholding approach was employed to generate binary networks, allowing a robust comparison of connectivity disruptions associated with AD.
methodBrain network features derived from the graph Laplacian, including weighted Fiedler value, spectral range, and Middle Eigenvalue, were analyzed across seven frequency layers: delta, theta, alpha1, alpha2, beta1, beta2, and gamma. For binary networks, the Fiedler value was calculated after thresholding. Statistical group comparisons between AD and HC were performed using t-tests (p < 0.05), and each feature was assessed based on the number of frequency bands showing significant differences.
resultsAmong all features, the weighted Fiedler value was the most discriminative, showing significant reductions in AD patients within the alpha2 and beta1 bands. In binary networks, the Fiedler value remained significantly lower in AD within the alpha2 band, confirming topological degradation even without edge weight information. Other spectral features showed similar trends, but did not reach statistical significance in the binary networks. DISCUSSION: The consistent decline in Fiedler value across both weighted and binary networks indicates a global reduction in connectivity characteristic of AD. These spectral markers offer a quantitative and interpretable framework for understanding the progressive disconnection syndrome in AD.
conclusionThis study demonstrates significant alterations in Laplacian spectral features of brain networks between the AD and HC groups across specific frequency bands. These exploratory findings indicate that the spectral features, particularly the Fiedler value, consistently differentiate AD patients from healthy controls across frequency bands, suggesting its potential as a biomarker. However, larger and longitudinal studies are needed to confirm its diagnostic and prognostic utility. The combined use of weighted and binarized connectivity matrices enhances analytical sensitivity and facilitates the application of spectral graph theory for the early detection and monitoring of AD.
Indexed as
Identifiers
41140215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.